ÇüÁú¼¼Æ÷Á¾¾çÀÇ Áø´Ü¿¡¼­ ¼±º°°Ë»çµéÀÇ À¯¿ë¼º °ËÅä
Evaluation of the Screening Tests for the Diagnosis of Plasma Cell Neoplasm

Laboratory Medicine Online 2012³â 2±Ç 2È£ p.80 ~ p.86

ȲÀ¯¼±(Hwang Yu-Sun) - ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø Áø´Ü°Ë»çÀÇÇб³½Ç
Á¤È­¼ø(Chung Wha-Soon) - ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø Áø´Ü°Ë»çÀÇÇб³½Ç
È«±â¼÷(Hong Ki-Sook) - ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø Áø´Ü°Ë»çÀÇÇб³½Ç

Abstract

Background:
Plasma cell neoplasm is diagnosed by performing bone marrow examination, serum- and urine-protein electrophoresis, and quantification of free light chains of immunoglobulins. We characterized and quantified monoclonal proteins typical of different diagnosed conditions to determine the best screening test(s).

Methods: We retrospectively reviewed diagnosis of and the characteristics of monoclonal proteins from 113 patients with monoclonal gammopathy. Monoclonal proteins were detected by agarose-gel electrophoresis and capillary electrophoresis, and if the results were ambiguous, they were confirmed by immunofixation electrophoresis. Free light chains were measured using nephelometry.

Results: The concentrations of monoclonal proteins in 113 patients with different conditions were as follows: multiple myeloma (MM) (67%), 2.66 (0.87-9.48) g/dL; monoclonal gammopathy of undetermined significance (MGUS) (26%), 0.62 (0.08-2.95) g/dL; lymphoma (3%), 3.65 (1.59-6.54) g/dL; Waldenstrom's macroglobulinemia (2%), 1.99 (1.08-2.90) g/dL; amyloidosis (2%), 0.61 g/dL; and POEMS syndrome (1%), 0.99 g/dL. There was a significant difference in the concentration and ¥ê/¥ë ratio (which was based on the immunetype of the monoclonal proteins) of the monoclonal proteins in patients with MM and MGUS (P<0.001 and P=0.004, respectively). The diagnostic sensitivity of serum-protein electrophoresis, free-light-chain assay, and bone marrow analysis was 87.6%, 84.1%, and 84.5%, respectively. The sensitivity of a combination of 2 or 3 of these tests was higher at 100%.

Conclusions: A combination of protein electrophoresis with immunotyping and serum free-light-chain assay may be the best screening method for detecting monoclonal proteins since its non-invasiveness.

Å°¿öµå

Plasma cell neoplasm, Monoclonal protein, Screening test
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
KoreaMed 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
: A combination of protein electrophoresis with immunotyping and serum free-light-chain assay may be the best screening method for detecting monoclonal proteins since its non-invasiveness.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå